Genzyme, a Sanofi Company

Quick facts

Marketed products

• Myozyme · Rare Disease · revenue 1100
• Aldurazyme · Other
• Alemtuzumab (GZ402673) · Immunology / Hematology
  Alemtuzumab is a monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction and depletion.
• ALGLUCOSIDASE ALFA (MYOZYME) · Rare genetic disease / Metabolic disorder
  Alglucosidase alfa is a recombinant human acid alpha-glucosidase enzyme that breaks down glycogen accumulated in lysosomes, restoring normal cellular function in Pompe disease.
• Calcium-based phosphate binder
• Caprelsa · Oncology
• Colesevelam hydrochloride film-coated tablets
• doxercalciferol capsules, Hectorol® · Endocrinology / Nephrology
  Doxercalciferol is a vitamin D analog that activates the vitamin D receptor to regulate calcium and phosphate metabolism and suppress parathyroid hormone (PTH) secretion.
• doxercalciferol capsules, Hectorol® capsules · Endocrinology / Nephrology
  Doxercalciferol is a vitamin D analog that activates the vitamin D receptor to regulate calcium and phosphate metabolism and suppress parathyroid hormone secretion.
• Fabrazyme (agalsidase beta) · Metabolic
• Fitusiran (SAR439774) · Hematology
  Fitusiran is an RNA interference (RNAi) therapeutic that silences antithrombin (AT) messenger RNA to reduce antithrombin levels and enhance the intrinsic coagulation pathway, thereby increasing thrombin generation in patients with hemophilia.
• Fixed Dose Plerixafor · Oncology
  Plerixafor is a CXCR4 antagonist that mobilizes hematopoietic stem cells from the bone marrow into peripheral blood for collection and transplantation.
• Myozyme® (alglucosidase alfa) · Rare genetic disease / Metabolic disorder
  Alglucosidase alfa is a recombinant human acid alpha-glucosidase enzyme that breaks down glycogen accumulated in lysosomes, restoring normal cellular function in Pompe disease.
• Weight-Based Plerixafor

Phase 3 pipeline

• Alglucosidase alfa (GZ419829) · Rare Genetic Disorder / Metabolic Disease
  Alglucosidase alfa is a recombinant human acid alpha-glucosidase enzyme that breaks down glycogen accumulated in lysosomes in Pompe disease.
• BPA prophylaxis · Immunology / Transplantation
  BPA prophylaxis prevents breakthrough polyomavirus-associated nephropathy (BPA) in immunocompromised patients, likely through antiviral or immunomodulatory mechanisms.
• Calcium acetate (PhosLo® ) · Nephrology
  Calcium acetate binds to dietary phosphate in the gastrointestinal tract to reduce serum phosphate levels in patients with hyperphosphatemia.
• Ceterizine · Other
• clofarabine (IV formulation) · Oncology
  Clofarabine is a nucleoside analog that interferes with DNA synthesis, leading to cell death in rapidly dividing cancer cells.
• factor concentrates · Hematology
  Factor concentrates replace or supplement deficient clotting factors to restore hemostatic function in patients with bleeding disorders.
• FluCAM [Fludara + Campath] · Oncology
  FluCAM combines a purine nucleoside analog that inhibits DNA synthesis with a monoclonal antibody that depletes lymphocytes, providing dual immunosuppressive and cytotoxic activity.
• Generic = Plerixafor · Oncology
  Plerixafor is a CXCR4 chemokine receptor antagonist that mobilizes hematopoietic stem cells from the bone marrow into peripheral blood.
• Thyrogen + Radioiodine (131I) · Oncology
  Thyrogen (recombinant human TSH) stimulates thyroid tissue to take up radioiodine (131I), enabling targeted destruction of thyroid cancer cells and metastases.
• Vandetanib (SAR390530) · Oncology
  Vandetanib is a tyrosine kinase inhibitor that targets RET, VEGFR2, and EGFR.

Phase 2 pipeline

• 131I · Oncology
  Iodine-131 is a radioactive isotope that emits beta particles to destroy thyroid tissue and thyroid cancer cells.
• acetaminophen or paracetamol
• Alemtuzumab plus Fludarabine · Oncology
  Alemtuzumab is a monoclonal antibody targeting CD52, a protein found on the surface of mature lymphocytes. Fludarabine is a purine analog that inhibits DNA synthesis.
• Colesevelam Cholestagel · Cardiovascular, Endocrinology
  Colesevelam is a bile acid sequestrant that binds bile acids in the intestine to prevent their reabsorption, thereby lowering LDL cholesterol and improving glycemic control.
• Enteric coated sevelamer · Nephrology
  Sevelamer binds to phosphate ions in the gastrointestinal tract, reducing phosphate absorption.
• Fetal porcine cells, Neurocell-PD
• G-CSF and plerixafor · Oncology
  Stimulates the production of neutrophils by binding to the G-CSF receptor
• GC1008
• Genz-644470
• GT160-246
• GZ389988
• GZ402665 · Oncology
  GZ402665 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.
• ILX651 · Oncology
  ILX651 is a small molecule inhibitor of the sodium-iodide symporter (NIS) with potential use in thyroid cancer treatment.
• MRrhTSH
• plerixafor GZ316455
• sevelamer carbonate, sevelamer hydrochloride
• sevelamer hydrochloride, sevelamer carbonate

Phase 1 pipeline

• AAV2-sFLT01 · Oncology
  VEGF inhibitor
• eliglustat; digoxin
• Eliglustat, Phase 3 capsule formulation
• Genz-682452
• GZ402666
• GZ402668
• Modified Release rhTSH
• NM-3
• Recombinant human acid sphingomyelinase
• RG012

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Genzyme, a Sanofi Company portfolio CI brief
• Genzyme, a Sanofi Company pipeline updates RSS